NASDAQ · Biotechnology

LGND (LGND) Stock

$284.27 +0.06% NASDAQ: LGND Healthcare

Valuation

MetricValue
Price$284.27
Market Cap$5.70B
P/E Ratio28.38
P/B Ratio5.89
P/S Ratio19.60
EPS (TTM)$7.66
52-Week High$326.63
52-Week Low$160.80
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE20.06%
ROA9.02%
ROCE4.72%
Gross Margin83.16%
Operating Margin33.58%
Net Margin67.88%
Debt/Equity1.17
Current Ratio21.28

Annual Financials (USD)

Metric20212022202320242025
Revenue$242.0M$196.0M$131.0M$167.0M$268.0M
Operating Profit$104.0M$3.0M$12.0M$-23.0M$47.0M
Net Profit$57.0M$-33.0M$52.0M$-4.0M$124.0M
EPS$3.34$-1.98$2.94$-0.22$6.13
Op Margin43.0%1.6%9.1%-13.5%17.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.3B$763.0M$787.0M$942.0M$1.6B
Total Liabilities$476.0M$165.0M$86.0M$111.0M$543.0M
Cash$20.0M$45.0M$23.0M$72.0M$175.0M
Borrowings$324.0M$88.0M$6.0M$7.0M$451.0M

Latest News

Ligand Pharmaceuticals Insider Sold Shares Worth $1,566,377, According to a Recent SEC Filing MT Newswires · Jul 6, 2026 Ligand Pharmaceuticals Closes Offering of Senior Notes due 2031 MT Newswires · Jun 25, 2026 Ligand Announces Closing of Convertible Senior Notes Offering GlobeNewswire · Jun 25, 2026 Ligand Pharmaceuticals Prices Upsized $625 Million Convertible Notes Offering MT Newswires · Jun 23, 2026 Ligand Announces Pricing of Upsized $625 Million Convertible Senior Notes Offering GlobeNewswire · Jun 23, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$79.0M$138.0M$50.0M$97.0M$49.0M
Investing Cash Flow$22.0M$146.0M$-66.0M$-163.0M$-378.0M
Financing Cash Flow$-26.0M$-18.0M$-5.0M$60.0M$-25.0M
Net Cash Flow$-28.0M$25.0M$-22.0M$49.0M$103.0M
Free Cash Flow$70.0M$120.0M$-4.0M$77.0M$49.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.03
EV / EBITDA21.26
FCF Yield2.31%
Quick Ratio30.96
Interest Coverage16.31
Return 1Y75.35%
Return 3Y335.75%
Return 5Y299.09%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACAD $28.89 -0.07% 8.94 $4.95B 0.00%
ADMA $9.33 -0.64% 12.17 $2.16B 0.00%
BLTEBelite Bio, Inc $157.14 -2.45% -61.62 $6.30B 0.00%
CRNX $84.95 +0.00% -16.80 $9.00B 0.00%
DYN $25.10 -1.30% -7.64 $4.69B 0.00%

About LGND

LGND stock trades at $284.27 with a market capitalization of $5.70B. The stock is valued at a price-to-earnings (P/E) ratio of 28.38, price-to-book of 5.89, price-to-sales of 19.60. Over the past 52 weeks the stock has ranged between $160.80 and $326.63, and currently trades 13.0% below its 52-week high.

On profitability, LGND generates a return on equity (ROE) of 20.06% — well above the market average, a sign of a high-quality business, return on capital employed of 4.72%, an operating margin of 33.58%, a net profit margin of 67.88%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1159.93 +0.28% JNJ Drug Manufacturers - General $271.19 +2.01% ABBV Drug Manufacturers - General $259.99 +1.39% MRK Drug Manufacturers - General $149.94 +1.48% UNH Medical - Healthcare Plans $396.30 +1.77% NVS Drug Manufacturers - General $161.25 +6.04% AZN Drug Manufacturers - General $162.47 +0.21% AMGN Drug Manufacturers - General $438.12 +1.92% TMO Medical - Diagnostics & Research $600.50 -2.69% NVO Biotechnology $45.12 -0.46% ABT Medical - Devices $108.97 -1.26% GILD Drug Manufacturers - General $149.92 +2.45%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides